BioCryst Pharma (BCRX) Tops Q1 EPS by 4c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.92 +2.27%
Revenue Growth %: +3.9%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +3.9%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $92.76 million versus the consensus estimate of $85.82 million.
GUIDANCE:
BioCryst Pharma sees FY2024 revenue of $390-400 million, versus the consensus of $395.1 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Stifel Starts Tower Semiconductor (TSEM) at Buy, Top Pick
- Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
